Beschreibung
Both escitalopram and hydroxychloroquine prolong the QT interval; their concurrent use markedly increases the risk of potentially fatal arrhythmias.
Mechanismus
Both agents block hERG channels in a dose-dependent manner, producing additive prolongation of the QTc interval.
Klinische Bedeutung
FDA safety communications highlight QT prolongation risk for both drugs; their combination is considered high risk in patients with risk factors.
Maßnahmen
Avoid combination or use with extreme caution; obtain baseline ECG, monitor QTc throughout therapy, and correct electrolytes.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.